research compound is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
The story and cast performances were positively received; Time Out magazine called it "flawed but impressive". Afterward, he starred in Rob Reiner's 2007 comedy The Bucket List opposite Jack Nicholson. The plot follows two terminally ill men on a road trip with a list of things to do before they die. The film grossed $175 million worldwide.
== Rankings == The 2026 SCImago Institutions Rankings health-sector ranking for dentistry placed the West China Hospital of Stomatology first in China and third worldwide. In the 2025 ShanghaiRanking Global Ranking of Academic Subjects, Sichuan University was ranked fifth in the world in Dentistry & Oral Sciences. In the 2026 QS World University Rankings by Subject, Sichuan University was ranked 10th in the world for dentistry.
Amides are pervasive in nature and technology. Proteins and important plastics like nylons, aramids, Twaron, and Kevlar are polymers whose units are connected by amide groups (polyamides); these linkages are easily formed, confer structural rigidity, and resist hydrolysis. Amides include many other important biological compounds, as well as many drugs like paracetamol, penicillin and LSD. Low-molecular-weight amides, such as dimethylformamide, are common solvents.
Sources: en.wikipedia.org
===== Response to stimuli ===== Serotonin is important in environmental response pathways, along with other neurotransmitters. Specifically, it has been found to be involved in auditory processing in social settings, as primary sensory systems are connected to social interactions. Serotonin is found in the IC structure of the midbrain, which processes specie specific and non-specific social interactions and vocalizations. It also receives acoustic projections that convey signals to auditory processing regions. Research has proposed that serotonin shapes the auditory information being received by the IC and therefore is influential in the responses to auditory stimuli. This can influence how an organism responds to the sounds of predatory or other impactful species in their environment, as serotonin uptake can influence aggression or social interaction.
The results of studies which have looked at healing of electrosurgical wounds compared to scalpel wounds vary widely but it has been found that electrosurgerical equipment minimises bleeding and most patients experience very little post-operative pain after the procedure. There may be more damage to adjacent tissues, slower wound healing and more inflammatory response than the scalpel technique.
Interest in a possible island of stability grew throughout the 1960s, as some calculations suggested that it might contain nuclides with half-lives of billions of years. They were also predicted to be especially stable against spontaneous fission in spite of their high atomic mass. It was thought that if such elements exist and are sufficiently long-lived, there may be several novel applications as a consequence of their nuclear and chemical properties. These include use in particle accelerators as neutron sources, in nuclear weapons as a consequence of their predicted low critical masses and high number of neutrons emitted per fission, and as nuclear fuel to power space missions. These speculations led many researchers to conduct searches for superheavy elements in the 1960s and 1970s, both in nature and through nucleosynthesis in particle accelerators. During the 1970s, many searches for long-lived superheavy nuclei were conducted. Experiments aimed at synthesizing elements ranging in atomic number from 110 to 127 were conducted at laboratories around the world. These elements were sought in fusion-evaporation reactions, in which a heavy target made of one nuclide is irradiated by accelerated ions of another in a cyclotron, and new nuclides are produced after these nuclei fuse and the resulting excited system releases energy by evaporating several particles (usually protons, neutrons, or alpha particles).
Sources: en.wikipedia.org
== History == Cell display systems were first used in 1985, when peptides were genetically fused with proteins displayed on the M13 bacteriophage. Bacteriophage display is a commonly used cell display system, although it carries limitations in the size of proteins that can be displayed. Bacterial display was then introduced in 1986, allowing the surface display of larger proteins. Bacterial display systems were first introduced by Freudl et al. and Charbit et al. in 1986, when they used bacterial surface proteins OmpA and LamB to display peptides. Freudl et al. fused peptides with linkers with the ompA gene, causing the peptides to be expressed in the OmpA proteins. They showed that the proteins were now subject to cleavage by proteinase K. The non-OmpA peptides inserted were therefore a target of proteinase K. Insertion of the foreign peptides did not affect bacterial cell growth. Charbit et al. firstly defined the areas of the LamB protein that were "permissive" for foreign petide insertion (ie that did not lead to a complete loss of functionality of the protein). Then, they explored the versatility of the permissive sites (size limit, nature of the epitope,...) that were all located in surface-exposed loops of the trimeric outer membrane porin, aiming at developing multivalent live bacterial vaccines. This was the first evidence of using bacterial surface display techniques to express proteins on the surface of cells, without altering the function of the cell.
== Regulation of glucagon secretion == There are several methods of control of the secretion of glucagon. The most well studied is through the action of extra-pancreatic glucose sensors, including neurons found in the brain and spinal cord, which exert control over the alpha cells in the pancreas. Indirect, non-neuronal control has also been found to influence secretion of glucagon.
With the end of apartheid after the first multi-racial elections and the coming into force of the Interim Constitution of South Africa on 27 April 1994, Bophuthatswana ceased to exist and once again became part of South Africa. The majority of the country became part of the North West province, while the Thaba 'Nchu district became part of the Free State, and the Mathanjana exclave north-east of Pretoria became part of Mpumalanga. The capital, Mmabatho, was merged with Mafikeng and the combined city is now the capital of the North-West province.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.